Advanced Gastric Cancer

HER2

PF-00299804 will be given orally once daily at 45 mg daily. Patients will take study drug continuously, with cycles of 28 days.

PF00299804

Seoul National University Hospital

PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer

A Phase II Open Label Trial of PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer After Failure of At Least One Prior Chemotherapy Regimen

PFS is defined as the interval from the date of enrollment to the date of disease progression or death due to any cause, whichever occurs first. PFS4m is defined as the proportion of patients alive and progression-free at 4 months relative to all enrolled patients.

Overall Response Rate (BOR) per RECIST Confirmed responses are defined as those that persist on a follow-up imaging assessment 4 weeks after the initial objective documentation of response.

Overall Survival (OS), defined as the time from enrollment to the date of death due to any cause.

Overall Safety Profile, as characterized by type, frequency, severity as graded by NCI Common Toxicity Criteria for Adverse Events version 3.0 (NCI CTCAEv3.0), timing and relationship to treatment, and laboratory abnormalities observed.

cystine/rak dojke

PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer

Najbolj popolna baza zdravilnih zelišč, podprta z znanostjo